NCT06660446 Exercise During Chemotherapy Treatment As Adjuvant Program in Patients with Lymphoma: EDONOLA Study.
| NCT ID | NCT06660446 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Biogipuzkoa Health Research Institute |
| Condition | Lymphoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 180 participants |
| Start Date | 2024-10-08 |
| Primary Completion | 2027-03-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 180 participants in total. It began in 2024-10-08 with a primary completion date of 2027-03-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In people diagnosed with lymphoma receiving immunochemotherapy treatment, a combined exercise intervention, as opposed to the general recommendations, will achieve: 1.Improve cardiorespiratory fitness, strength, psychological well-being and quality of life. //2.Reduce fatigue//3.Reduce frailty There is an association between some biological biomarkers with physical capacity and frailty.
Eligibility Criteria
Inclusion Criteria: * Age: ≥18 years old. * Diagnosis of lymphoma with histological confirmation and requirement of systemic treatment including chemotherapy. * Time available (80 minutes, two days a week for 20 weeks) to carry out physical exercise sessions. * Have a mobile phone to be able to contact the person and download the physical activity level app. * Eastern Cooperative Oncology Group performance status (ECOG) ≤2. * Life expectancy \>12 months. * Availability and desire to participate throughout the study period. Exclusion Criteria: * Have a contraindication to moderate-high intensity exercise. * Other significant medical disorders: including psychiatric illnesses chronic or recurrent; intellectual disability, musculoskeletal problems, cardiac or pulmonary disorders that interfere with physical exercise; other malignant tumors in the last five years, with the exception of therapeutically controlled skin cancer; any other illness that may be seen affected or aggravated by physical exercise. * Have plans to be outside city more than two weeks. * People who are already physically active (that comply with the recommendations of WHO: \> 150 minutes of exercise moderate/weekly, plus training force two days/week). * Treatment based only with immunotherapy. * Central nervous system involvement due to lymphoma. * Have any important history that limit the capacity of the patient to participate in the study.
Contact & Investigator
Clinical Research Platform - Health Research Institut Biogipuzkoa
✉ OSID.INVESTCLINICA@osakidetza.eus📞 +34943006140
Izaskun Zeberio Etxetxipia
PRINCIPAL INVESTIGATOR
Hospital Donostia
Frequently Asked Questions
Who can join the NCT06660446 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06660446 currently recruiting?
Yes, NCT06660446 is actively recruiting participants. Contact the research team at OSID.INVESTCLINICA@osakidetza.eus for enrollment information.
Where is the NCT06660446 trial being conducted?
This trial is being conducted at Vitoria - Gateiz, Spain, Galdakao, Spain, San Sebastián, Spain.
Who is sponsoring the NCT06660446 clinical trial?
NCT06660446 is sponsored by Biogipuzkoa Health Research Institute. The principal investigator is Izaskun Zeberio Etxetxipia at Hospital Donostia. The trial plans to enroll 180 participants.